STOCK TITAN

Evaxion Biotech A/S - EVAX STOCK NEWS

Welcome to our dedicated news page for Evaxion Biotech A/S (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evaxion Biotech A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evaxion Biotech A/S's position in the market.

Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) closes private placement with gross proceeds of $5.3 million, including a 25% investment from MSD Global Health Innovation Fund. The private placement involved the sale of 9,726,898 ordinary shares represented by ADSs and accompanying warrants. The company plans to use the proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announced its refined strategy with increased focus on value realization via partnerships based on the AI-Immunology™ platform. The company reported solid progress with two partnerships announced in Q3 and proof-of-principle for Evaxion’s proprietary responder model. They also priced a bridge financing round expected to raise $5.3 million, aiming to fund operations until March 2024. The company aims to fund 2024 cash burn with income from business development activities, expecting cash burn at the level of $14 million in 2024. Evaxion's CEO highlighted the refined strategy's focus on value realization and reduced cash burn, emphasizing strong business execution based on the new strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
earnings
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announces a private placement financing to raise gross proceeds of approximately $5.3 million, with MSD Global Health Innovation Fund (MSD GHI) contributing 25% of the total offering amount. The Private Placement includes participation from existing and new shareholders, with significant involvement from the Company’s management and board of directors. The Private Placement involves the issuance and sale of 9,726,898 of the Company’s ordinary shares and accompanying warrants at a purchase price of $0.544 per Ordinary Share for an aggregate purchase price of $5.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
Rhea-AI Summary
Evaxion Biotech (EVAX) presents breakthrough achievement in precision cancer vaccines at the 65th ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
AI
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) presents a novel AI model at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany, designed to predict patient responses to cancer immunotherapy. The model aims to improve patient outcomes, reduce healthcare costs, and is scalable for broader applications. Evaxion plans to pursue a partnership-based approach towards a commercial offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
AI
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is hosting an online webinar on November 8th featuring Professor Adnan Khattak, the principal investigator of the EVX-01 clinical trial. EVX-01 is Evaxion's lead clinical asset based on its AI-Immunology™ platform. The webinar will discuss the promising results of the Phase 1 trial and provide an update on the Phase 2 trial, which appears to confirm the benefits of this innovative immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
clinical trial
Rhea-AI Summary
Evaxion Biotech announces positive initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings. The trial showed a significant and continuous tumor reduction in a metastatic melanoma patient with initial progressive disease. The company's AI-Immunology™ platform demonstrated the ability to identify therapeutically relevant cancer vaccine targets. A comprehensive clinical update will be presented at the Society for Immunotherapy of Cancer (SITC) 38th annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.79%
Tags
clinical trial
-
Rhea-AI Summary
Evaxion Biotech will present clinical readouts on its two personalized cancer vaccine trials at the annual meeting of the Society for Immunotherapy of Cancer. The results will be presented in two posters, showcasing the positive clinical evidence for the company's AI-immunology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.59%
Tags
clinical trial AI
-
Rhea-AI Summary
Evaxion Biotech receives notification letter from Nasdaq regarding bid price deficiency
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Evaxion Biotech announces collaboration with Afrigen Biologics for the development of a gonorrhea vaccine based on Evaxion's EDEN™ platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
partnership
Evaxion Biotech A/S

Nasdaq:EVAX

EVAX Rankings

EVAX Stock Data

14.43M
24.92M
17.99%
1.01%
0.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Denmark
Horsholm

About EVAX

since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai